Advanced Life Sciences news from FierceBiotech
NewsC&L: Wells named Biovail CEO
Biovail has named William Wells, Loblaw Cos. Ltd.'s chief financial officer, as its new chief executive, replacing Douglas Squires, who will become Biovail's chairman. ARUP Laboratories co-founder Read more...
ALS sees strong data in Phase III antibiotic trial
Advanced Life Sciences is touting data from a recent trial of its antibiotic cethromycin. The therapy produced positive data that it can fight pneumonuia effectively and safely and demonstrated an Read more...
ALSO NOTED: Pharmaxis touts late-stage study; ALS gains orphan drug status; H5N1 passed human-to-human; and much more...
> Pharmaxis says that a late-stage study of its experimental drug for a chronic lung condition demonstrated its effectiveness. Read more...
| Press ReleasesPRESS RELEASE: Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia Trial CL-05 Results Showed Cethromycin had 94.0% Clinical Cure Rate Compared to 93.8% Clinical Cure Read more... |
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets